Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2004

View Archived Issues

New data on the neurological effects of methotrexate

Imiquimod in the treatment of AIN in HIV-infected men

Microbicidal properties found for lemon and lime juice

Preclinical data on the pharmacokinetics and toxicology of prostratin

Potent uPA inhibitor selected for clinical evaluation at Pfizer

Vanillin prodrug may be effective for patients with sickle cell disease

Encouraging results for MF-5232 for mucositis

NIAID expands West Nile virus study

FDA approves Reyataz sNDA

Preclinical milestone in BioInvent and Cartela osteoarthritis collaboration

NIAID to exercise malaria vaccine contract option with Epimmune

Elan to produce reformulated Panzem for EntreMed oncology program

Fourth phase II study of PI-88 launches

(PE)HRG214 reduces viral load in HIV-infected patients

Statins reported to reduce HIV-1 replication

MIV-150 as a vaginal microbicide for HIV-infected women

FDA Advisory Committee recommends against approval of oral tazarotene

BLX-1002 improves metabolic syndrome-type abnormalities in fructose-fed rats

Mandelic acid derivatives claimed for inhibiting coagulation factors

Biaryl compounds with antibiotic properties described by AstraZeneca

Bayer discloses gamma-secretase inhibitors

Scientists at Lilly describe vitamin D receptor modulators

Antitumor sulfonamides claimed by Lilly

Tibotec discloses antiinfective compounds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...